Treatment(s) now being considered-Other Page 2 Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Other Posts on Medivizor

Phase I trial to determine the safety of a new anti-cancer drug: PD 0332991

Posted by on Mar 11, 2013 in Breast cancer | 0 comments

In a nutshell This article presents the results from the first human trial of PD 0332991, a new anti-cancer drug. The main objective of the study was to determine the safety and recommended dose for further testing. Results warrant further studies and revealed that neutropenia (low white cell count) was the main side effect. Some background Cells...

Read More

Regorafenib is a new drug for the treatment of metastatic colorectal cancer after failure of previous therapies

Posted by on Mar 10, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study evaluated the efficacy of a new drug, Regorafenib, for the treatment of refractory (progressing despite several lines of treatment) metastatic colorectal cancer (mCRC).  Some background Many of the patients with colorectal cancer do not present any symptoms in the early stages of the disease so the cancer...

Read More

Comparison of two surgical techniques for the treatment of pseudomyxoma peritonei

Posted by on Mar 4, 2013 in Colorectal cancer | 1 comment

In a nutshell The present study compared the efficacy of two surgical techniques to treat pseudomyxoma peritonei (PMP): debulking and cytoreduction. Cytoreductive surgery achieved better surgical results and yielded higher 3- and 5-year survival rates, compared with debulking. Some background PMP is a rare condition caused by the production of...

Read More

Combined safety results of 4 clinical trials using sipuleucel-T in patients with prostate cancer

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell The present study summarized the outcomes of four clinical trials assessing the side-effects reported with sipuleucel-T treatment in patients with prostate cancer. The combined results indicated that this drug is relatively safe with mostly mild to moderate, short-term, and reversible side-effects. Some background As of...

Read More

The use of systemic chemotherapy for patients with poorly differentiated and signet cell adenocarcinoma of the appendix

The use of systemic chemotherapy for patients with poorly differentiated and signet cell adenocarcinoma of the appendix

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study evaluated the effects of systemic chemotherapy and cytoreductive surgery (CRS) on survival in patients with aggressive types of cancer of the appendix (poorly differentiated and signet ring cell adenocarcinoma). The main findings were that systemic chemotherapy appears to be a viable treatment option for these types of...

Read More